Immune Checkpoint Inhibitor–Associated Remitting Seronegative Symmetrical Synovitis With Pitting Edema: Description of a New Entity by CanRIO
Authors' conclusion
ICI-RS3PE may be an independent Rh-irAE, separate from paraneoplastic RS3PE. The symptoms of ICI-RS3PE responded well to glucocorticoids, but concomitant treatment with csDMARDs may be necessary.
Study context
- Population
- Adult patients with rheumatic immune-related adverse events (irAEs) in the CanRIO network of Canadian rheumatologists
- Participants
- 11 patients
- Outcome
- Characteristics of ICI-RS3PE cases
Methodological detailsmulticentre, retrospective and prospective cohorts
- Multicentre
- Retrospective and prospective cohorts
Main finding
As reported in the abstract
- Nonsmall cell lung cancer (most frequent malignancy)
- 4 of 11
- Malignant melanoma
- 2 of 11
- Cutaneous squamous cell carcinoma
- 2 of 11
- Median time to onset from ICI start
- 26 weeks
- Median time to onset from diagnosis of malignancy
- 52 weeks
- Stable cancer prior to onset
- 7
- Partial response prior to onset
- 3
- Complete response prior to onset
- 1
- Received GC
- 11 (all patients)
- Conventional synthetic disease-modifying antirheumatic drugs (csDMARD) needed
- 10
Observational data: associations, not effects.
Original publication
Immune Checkpoint Inhibitor–Associated Remitting Seronegative Symmetrical Synovitis With Pitting Edema: Description of a New Entity by CanRIO. J Rheumatol. Published 1 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →